Maze Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule drugs for kidney and metabolic diseases. Maze's core differentiator is its proprietary Compass platform, which identifies genetic variants that protect against or cause disease, then designs drugs to mimic protective variants or block harmful ones. Maze has two wholly-owned clinical programs: MZE829, an oral APOL1 inhibitor for APOL1-mediated kidney disease (AMKD), a genetically defined form of CKD with no approved therapies that disproportionately affects people of West African ancestry; and MZE782, an oral SLC6A19 inhibitor targeting both PKU and CKD. MZE829 completed Phase 2 in early 2026, showing a mean 35.6% reduction in a key kidney disease biomarker, and Maze plans to advance it into a pivotal program. MZE782 showed positive Phase 1 data in 2025, with Phase 2 trials planned for 2026. Maze intends to self-commercialize both assets. Beyond its core pipeline, Maze out-licenses programs developed through the Compass platform that fall outside its focus areas — the most notable being MZE001, a GYS1 inhibitor for Pompe disease licensed to Shionogi for a $150M upfront payment plus milestones and royalties. Maze also owns roughly 48% of Broadwing, a spin-out targeting glaucoma. Maze generates no product revenue today; its business model relies on R&D-driven pipeline advancement funded by cash from out-licensing deals, with long-term revenue dependent on advancing MZE829 and MZE782 through pivotal trials and to approval.